Hikma Pharmaceuticals (LON:HIK) Shares Pass Above 200-Day Moving Average – Time to Sell?

Shares of Hikma Pharmaceuticals PLC (LON:HIK) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 1,460.77 and traded as high as GBX 1,494. Hikma Pharmaceuticals shares last traded at GBX 1,474.39, with a volume of 508,198 shares.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on HIK. Berenberg Bank restated a “buy” rating and issued a GBX 1,800 price target on shares of Hikma Pharmaceuticals in a research note on Tuesday, April 28th. Jefferies Financial Group raised their price target on Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the stock a “buy” rating in a research note on Tuesday, May 5th. Five equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of GBX 2,128.

Hikma Pharmaceuticals Trading Down 0.2%

The company has a market capitalization of £3.17 billion, a P/E ratio of 8.15, a PEG ratio of 2.38 and a beta of 0.64. The company has a debt-to-equity ratio of 63.59, a quick ratio of 1.27 and a current ratio of 1.82. The stock has a fifty day moving average of GBX 1,361 and a 200 day moving average of GBX 1,460.77.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.